Antithrombotic therapy in coronary artery disease: strategy choice based on comorbidity. A review
Open Access
- 20 April 2026
- journal article
- review article
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (1) , 28-35
Abstract
Coronary artery disease (CAD) remains a leading cause of mortality, and its frequent coexistence with atrial fibrillation (AF) significantly worsens prognosis, presenting physicians with a complex choice between stroke prevention, protection from coronary events, and minimization of bleeding risk. Even in patients with stable CAD, a high residual risk of thrombotic complications persists, driven by ongoing activation of the coagulation cascade, which traditional antiplatelet monotherapy cannot fully control. The strategy of dual pathway inhibition of thrombus formation has improved treatment outcomes: adding rivaroxaban at a "vascular" dose of 2.5 mg twice daily to acetylsalicylic acid provides a significant reduction in the risk of cardiovascular death and ischemic events with an acceptable safety profile. This approach is justified in patients at high ischemic risk, particularly those with a history of myocardial infarction or multivessel CAD. In the presence of AF, the principles of antithrombotic protection fundamentally change, mandating the inclusion of full-dose anticoagulation. The key strategy to address this challenge is treatment de-escalation: from the shortest possible courses of triple therapy (anticoagulant plus two antiplatelet agents) in the acute phase after percutaneous coronary intervention to dual therapy (anticoagulant plus clopidogrel) during the first year of follow-up. In the long term, stable patients benefit from a transition to anticoagulant monotherapy, which is non-inferior to combination therapy in preventing thrombotic events and significantly superior in terms of safety, as confirmed by large clinical trials and meta-analyses. Thus, rivaroxaban possesses the most comprehensive evidence base among direct oral anticoagulants, covering the entire spectrum of clinical scenarios, from secondary prevention in isolated CAD to the management of patients with concomitant AF. This enables a truly individualized approach, carefully balancing ischemic and bleeding risks in real-world clinical practice.Keywords
This publication has 37 references indexed in Scilit:
- Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery DiseaseJAMA Cardiology, 2025
- Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover studyDiabetes Research and Clinical Practice, 2025
- Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome AnalysisAmerican Journal of Cardiovascular Drugs, 2022
- Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary StentingJACC: Cardiovascular Interventions, 2021
- Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trialsInternational Journal of Cardiology, 2020
- Meta-Analysis Comparing Double Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery DiseaseThe American Journal of Cardiology, 2020
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trialThe Lancet, 2018
- Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialAmerican Heart Journal, 2017
- Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary SyndromesJACC, 2015
- Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With AtherothrombosisJAMA, 2010